thetadefensin
hdefensin
macrocycl
antimicrobi
peptid
express
leukocyt
old
world
monkey
peptid
broad
spectrum
microbicid
vitro
numer
hdefensin
isoform
identifi
granulocyt
rhesu
macaqu
oliv
baboon
sever
mammalian
aand
bdefensin
genet
relat
hdefensin
proinflammatori
immuneactiv
properti
bridg
innat
acquir
immun
current
studi
analyz
immunoregulatori
properti
rhesu
hdefensin
rtd
abund
hdefensin
macaqu
reduc
level
tnf
secret
blood
leukocyt
stimul
sever
tlr
agonist
rtd
suppress
level
solubl
tnf
releas
bacteriaor
lpsstimul
blood
leukocyt
monocyt
despit
highli
conserv
conform
amino
acid
sequenc
antitnf
activ
rtd
vari
much
system
administ
nontox
balbc
mice
escal
intraven
dose
well
toler
nonimmunogen
adult
chimpanze
peptid
highli
stabl
serum
plasma
singl
dose
administr
mgkg
significantli
improv
surviv
balbc
mice
e
coli
periton
cecal
ligationandpunctur
induc
polymicrobi
sepsi
peptid
treatment
reduc
serum
level
sever
inflammatori
cytokineschemokin
bacterem
anim
collect
result
indic
antiinflammatori
properti
hdefensin
vitro
vivo
mediat
suppress
numer
proinflammatori
cytokin
blockad
tnf
releas
may
primari
effect
antimicrobi
peptid
play
major
role
host
defens
function
mammalian
granulocyt
defensin
express
leukocyt
andor
epithelia
mammal
studi
kda
cation
peptid
divid
three
structur
famili
b
hdefensin
base
distinct
tridisulfid
motif
aand
bdefensin
though
genet
distinct
share
similar
peptid
fold
wide
express
mammal
includ
human
defensin
three
structur
famili
first
recogn
antimicrobi
properti
vitro
collect
antimicrobi
spectrum
defensin
includ
bacteria
fungi
protozoa
virus
defensin
also
function
alarmin
elicit
adapt
respons
infect
tissu
injuri
hdefensin
isol
old
world
monkey
absent
higher
primat
includ
gorilla
chimpanze
human
peptid
macrocycl
backbon
posttransl
gener
pairwis
excis
headtotail
splice
two
nineresidu
segment
deriv
truncat
adefensinrel
precursor
nonapeptid
may
ident
homodimer
splice
deriv
differ
precursor
heterodimer
splice
thu
amplifi
divers
hdefensin
gene
encod
product
six
rhesu
macaqu
hdefensin
isoform
rtd
express
neutrophil
packag
cytoplasm
granul
specif
neutral
rtd
lysat
macaqu
neutrophil
granul
markedli
reduc
antimicrobi
activ
prepar
e
coli
aureu
c
albican
indic
promin
role
peptid
compon
pmn
antimicrobi
armamentarium
intranas
administr
protect
balbc
mice
lethal
infect
mous
adapt
strain
sarscoronaviru
sarscov
despit
fact
peptid
neutral
viru
vitro
protect
effect
vivo
correl
reduct
pulmonari
inflamm
suppress
sever
proinflammatori
cytokin
lung
homogen
character
immunoregulatori
properti
hdefensin
analyz
effect
natur
hdefensin
isoform
cytokinechemokin
respons
stimul
human
leukocyt
monocyt
test
efficaci
two
mous
model
bacterem
sepsi
result
studi
also
demonstr
cyclic
hdefensin
sequencespecif
antiinflammatori
properti
distinguish
human
neutrophil
adefensin
human
subject
blood
obtain
healthi
adult
volunt
provid
written
consent
particip
studi
consent
form
approv
institut
review
board
usc
protocol
anim
studi
anim
studi
approv
institut
anim
care
use
committe
studi
perform
uc
irvin
protocol
mous
studi
univers
southern
california
protocol
mous
studi
texa
biomed
research
institut
protocol
chimpanze
studi
approv
anesthet
use
surgeri
recommend
analges
use
postop
care
everi
effort
made
minim
suffer
chimpanze
hous
social
group
indooroutdoor
hous
care
accord
us
public
health
servic
guid
care
use
laboratori
anim
us
anim
welfar
act
fed
standard
monkey
chow
supplement
fruit
veget
twice
daili
potabl
water
avail
enclosur
use
lixit
mechan
activ
environment
enrich
program
anim
anim
train
implement
reduc
stress
accomplish
anim
husbandri
procedur
cooper
studi
blood
sampl
compound
administr
perform
anesthet
anim
suffer
mitig
primat
sacrif
studi
anim
return
respect
group
upon
recoveri
anesthesia
hydrochlorid
salt
rtd
synthes
describ
previous
human
neutrophil
adefensin
physiolog
mixtur
hnp
purifi
purifi
human
neutrophil
previous
describ
stock
solut
peptid
mgml
prepar
acet
acid
hoac
vitro
analys
nacl
administr
anim
staphylococcu
aureu
escherichia
coli
obtain
atcc
manassa
va
clinic
isol
e
coli
obtain
clinic
laboratori
univers
california
irvin
medic
center
bacteria
cultur
singl
coloni
harvest
previous
describ
bacteria
wash
suspend
either
mm
piperazinen
acid
pipe
ph
phosphat
buffer
salin
pb
bacteri
densiti
determin
spectrophotometr
absorb
nm
correl
coloni
form
unit
tryptic
soy
agar
plate
tolllik
receptor
tlr
agonist
obtain
invivogen
san
diego
ca
use
recommend
manufactur
monocyt
cell
atcc
manassa
va
grown
maintain
medium
contain
fetal
bovin
serum
penicillinstreptomycin
cell
harvest
centrifug
wash
medium
suspend
cellsml
fresh
medium
contain
human
edta
plasma
cytokinechemokin
releas
assay
edtaanticoagul
blood
obtain
healthi
adult
volunt
approv
institut
review
board
usc
protocol
peripher
blood
leukocyt
pbl
harvest
ml
whole
blood
centrifug
g
cell
wash
twice
ml
rpmi
count
hemocytomet
suspend
cell
densiti
cellsml
rpmi
human
edtaplasma
pbl
stimul
h
either
mgml
ngml
typhimurium
flagellin
cfuml
heatkil
l
monocytogen
hklm
ngml
e
coli
lp
cfuml
clinic
e
coli
isol
cytokineschemokin
quantifi
use
milliplex
map
kit
biorad
bioplex
htf
luminex
reader
beckman
center
immun
monitor
uscnorri
cancer
center
peptid
rtd
human
neutrophil
adefensin
aliquot
well
pyrogenfre
plate
wherein
final
peptid
concentr
mgml
well
inocul
cfuml
aureu
cfuml
e
coli
ngml
e
coli
lp
sampl
ml
contain
peptid
bacterialp
place
opposit
side
plate
well
mix
commenc
addit
ml
dilut
blood
pbl
ml
cell
cell
ml
plate
incub
co
h
gentl
mix
experi
bloodrpmi
e
coli
cell
mgml
preincub
binari
combin
minut
follow
incub
h
tnf
releas
incub
mixtur
centrifug
g
min
supernat
clarifi
centrifug
g
min
supernat
tnf
quantifi
sandwich
elisa
opteia
ii
bd
bioscienc
hu
tnfa
invitrogen
per
supplier
direct
use
spectramax
plate
reader
control
experi
effect
tnf
elisa
standard
curv
e
coli
lp
lonza
dissolv
endotoxinfre
water
effect
unitsml
incub
mgml
mgml
polymyxin
b
sigma
dissolv
hoac
ml
reaction
mixtur
min
sampl
ml
limulu
amoebocyt
lysat
lal
lonza
ad
incub
min
ml
lal
substrat
ad
incub
min
reaction
quench
ml
hoac
read
spectrophotometr
nm
mgml
final
concentr
incub
freshli
prepar
human
serum
edta
plasma
mgml
human
serum
albumin
pb
aliquot
remov
hour
interv
h
acidifi
addit
hoac
final
concentr
peptid
quantifi
sequenti
solid
phase
extract
strata
x
resin
quantit
rphplc
describ
previous
group
four
balbc
mice
receiv
daili
ml
subcutan
inject
contain
mg
per
kg
bodi
weight
twenti
four
h
fourth
inject
mice
euthan
co
blood
collect
cardiac
punctur
tissu
harvest
fix
buffer
formalin
histopatholog
examin
perform
section
heart
lung
liver
spleen
kidney
inject
site
skin
subcutan
tissu
basic
metabol
panel
uc
daviswilliam
r
pritchard
veterinari
medic
teach
hospit
perform
serum
sampl
obtain
cardiac
punctur
time
euthanasia
primat
studi
conduct
use
two
adult
chimpanze
yo
male
yo
femal
anim
infus
escal
dose
mgkg
day
respect
dissolv
ml
pyrogenfre
steril
salin
blood
specimen
obtain
anim
prior
administr
min
peptid
infus
comprehens
metabol
panel
complet
blood
count
differenti
perform
specimen
sampl
anim
also
obtain
day
similarli
analyz
serum
sampl
obtain
day
also
analyz
antibodi
dot
blot
analysi
describ
employ
antitetanu
toxoid
immunoreact
posit
control
six
week
old
balbc
mice
jackson
lab
hous
individu
provid
standard
chow
water
ad
libitum
periton
induc
singl
intraperiton
inject
cfu
logphas
e
coli
ml
pb
mice
treat
immedi
singl
subcutan
inject
mgkg
ml
normal
salin
normal
salin
alon
control
sham
challeng
carri
intraperiton
inject
salin
anim
monitor
day
euthan
becam
moribund
count
nonsurvivor
cytokinechemokin
analys
group
four
mice
treatment
group
euthan
hour
follow
intraperiton
challeng
blood
collect
cardiac
punctur
edtatub
plasma
prepar
twostep
centrifug
g
min
follow
g
min
solubl
cytokineschemokin
quantifi
use
mousespecif
milliplex
cytokinechemokin
kit
describ
polymicrobi
periton
induc
week
old
balbc
mice
clp
describ
briefli
laparotomi
perform
anesthet
anim
cecum
ligat
ileocec
valv
wall
cecum
punctur
twice
needl
surgic
wound
close
nylon
sutur
anim
fulli
recov
within
min
four
hour
follow
clp
surgeri
anim
receiv
ml
normal
salin
n
ml
normal
salin
contain
mg
kg
n
tail
vein
inject
separ
group
mice
n
treat
singl
administr
delay
h
clp
surgeri
anim
health
evalu
daili
day
mice
euthan
becam
moribund
valu
express
mean
sem
except
experi
n
indic
figur
legend
data
express
standard
deviat
signific
peptid
effect
cytokin
determin
student
test
daili
survivaldeath
valu
determin
x
test
previou
studi
protect
mice
lethal
sarscov
via
mechan
independ
antivir
effect
viru
neutral
rather
administr
appear
protect
infect
anim
reduc
pulmonari
inflamm
suppress
kc
rant
day
postinfect
determin
modul
inflammatori
respons
human
cell
peripher
blood
leukocyt
pbl
incub
differ
tlr
agonist
without
mgml
evalu
releas
solubl
cytokineschemokin
initi
test
effect
ssrna
agonist
induc
respons
pbl
compar
human
cell
respons
obtain
mous
sarscov
singl
strand
rna
viru
pneumon
shown
figur
ssrna
stimul
human
leukocyt
induc
cytokineschemokin
similar
observ
murin
sarscov
pneumon
includ
tnf
simultan
addit
mgml
reduc
supernat
level
list
cytokinechemokin
suppress
rang
also
regul
leukocyt
releas
cytokin
chemokin
induc
tlr
agonist
hklm
flagellin
lp
live
e
coli
cell
fig
markedli
reduc
tnf
level
induc
hklm
lp
e
coli
cell
similar
effect
observ
treatment
ssrnastimul
cell
fig
expect
effect
leukocyt
respons
lp
e
coli
similar
effect
hklmstimul
cell
differ
somewhat
peptid
effect
leukocyt
activ
agonist
although
treatment
hklmstimul
cell
markedli
reduc
tnf
level
similar
effect
observ
agonist
increas
suppress
induc
level
chemokin
alon
littl
effect
cytokinechemokin
releas
leukocyt
except
vegf
lesser
degre
cytokin
evalu
experi
describ
tnf
regard
earliest
inflammatori
respons
signal
regard
function
trigger
numer
downstream
inflammatori
respons
investig
effect
tnf
releas
stimul
bacteri
antigen
anticoagul
human
blood
inocul
e
coli
aureu
stimul
e
coli
lp
presenc
vari
concentr
peptid
mixtur
block
stimul
tnf
releas
dosedepend
manner
mgml
aureu
mgml
e
coli
mgml
lp
fig
alon
effect
tnf
releas
blood
leukocyt
note
physiolog
mixtur
human
adefensin
hnp
tnfsuppress
effect
e
colistimul
pbl
fig
keep
previou
studi
cytotox
detect
incub
evidenc
lack
trypan
blue
stain
leukocyt
inhibit
lpsinduc
cytokinechemokin
releas
fig
suggest
peptid
might
bind
agonist
demonstr
antimicrobi
peptid
ineffect
neutral
e
coli
lp
fold
less
effect
polymyxin
b
fig
moreov
mix
polymyxin
b
show
addit
antagonist
effect
fig
result
indic
inhibit
endotoxinstimul
releas
tnf
via
mechan
lp
neutral
consist
find
potent
inhibitor
tnf
releas
pbl
stimul
multipl
tlr
agonist
fig
experi
summar
figur
modul
leukocyt
respons
analyz
follow
simultan
mix
peptid
inflammatori
stimulu
leukocyt
whole
blood
better
understand
sequenc
peptidemedi
tnf
blockad
mix
experi
perform
wherein
blood
peptid
e
coli
cell
preincub
vari
combin
see
method
tnf
releas
quantifi
describ
preincub
blood
h
effect
magnitud
tnfreleas
inhibit
quit
stabl
preincub
time
cours
fig
consist
effect
tnf
releas
e
coli
blood
mix
simultan
fig
contrast
premix
blood
e
coli
cell
h
follow
addit
show
timedepend
increas
tnf
releas
control
peptid
contain
mixtur
fig
howev
time
point
presenc
reduc
tnf
level
fig
result
indic
blockad
e
colistimul
tnf
releas
rapid
occur
immedi
addit
peptid
leukocytecontain
mixtur
fig
e
coli
cell
incub
prior
addit
blood
complet
blockad
tnf
releas
observ
timepoint
fig
wherea
e
coli
alon
elicit
increas
level
tnf
function
preincub
time
minut
preincub
interv
bacteri
count
increas
consist
tempor
rise
induc
tnf
releas
figur
effect
stimul
releas
cytokineschemokin
human
buffi
coat
cell
edtaanticoagul
blood
stimul
h
panel
tlr
agonist
mgml
ngml
typhimurium
flagellin
cfuml
heatkil
l
monocytogen
hklm
ngml
e
coli
lp
cfuml
e
coli
cell
level
ten
solubl
cytokineschemokin
measur
use
milliplex
map
kit
buffi
coat
cell
stimul
agonist
yellow
mgml
green
mgml
alon
red
solvent
control
hoac
blue
follow
addit
blood
fig
hand
absenc
viabl
bacteria
sampl
contain
reveal
e
coli
effici
kill
peptid
within
min
potent
inhibit
e
colistimul
tnf
releas
blood
leukocyt
experi
demonstr
rapid
blockad
bacteriastimul
tnf
releas
fig
moreov
bactericid
effect
termin
product
bacteri
antigen
base
bacteri
cell
number
tripl
h
absenc
fig
taken
togeth
data
summar
figur
suggest
interact
leukocyt
suppress
tnf
respons
microbi
antigen
abund
six
hdefensin
isoform
express
neutrophil
monocyt
rhesu
monkey
determin
rel
antiinflammatori
activ
hdefensin
isoform
rtd
fig
analyz
effect
peptid
tnf
level
e
coliblood
assay
describ
shown
figur
hdefensin
isoform
suppress
supernat
tnf
level
potenc
base
estim
rang
mgml
mm
rtd
substanti
effect
wherea
rtd
less
activ
analog
experi
perform
assess
effect
hdefensin
isoform
lpsstimul
monocyt
experi
rtd
inhibit
stimul
tnf
releas
vari
ca
fold
fig
note
hierarchi
antitnf
potenc
obtain
e
colistimul
blood
experi
ie
human
adefensin
inhibitori
effect
tnf
releas
either
assay
fig
c
also
see
fig
physiolog
mixtur
hnp
also
lack
tnf
inhibitori
activ
data
shown
vitro
experi
describ
confirm
reduct
cytokin
express
result
cytotox
effect
target
cell
trypan
blue
stain
confirm
cell
viabil
end
incub
interv
lack
cytotox
confirm
find
vegfa
express
increas
follow
treatment
fig
discuss
earlier
studi
nontox
host
cell
vitro
well
toler
administ
intranas
mice
current
studi
acut
toxic
observ
anim
receiv
subcutan
dose
mg
kg
highest
dose
test
serum
chemistri
mice
indistinguish
salinetr
control
histopatholog
examin
lung
kidney
heart
liver
spleen
treat
anim
show
abnorm
day
dose
regimen
peptid
level
test
detect
tissu
effect
associ
administr
focal
nonerythemat
swell
appear
inject
site
dorsal
midlin
thorac
skin
mice
day
mgkg
group
anim
day
mgkg
group
histolog
examin
affect
tissu
reveal
lobular
pannicul
fat
necrosi
around
inject
site
affect
anim
fig
escal
dose
mgkg
day
administ
intraven
two
adult
chimpanze
anim
evalu
clinic
effect
serum
chemistri
hematolog
paramet
clinic
inject
site
effect
observ
dose
level
period
studi
comprehens
metabol
panel
complet
blood
count
differenti
reveal
abnorm
associ
peptid
administr
time
point
studi
includ
obtain
dose
halt
day
ie
day
serum
sampl
time
point
also
evalu
antibodi
dot
blot
immunoassay
antitetanu
toxoid
antibodi
posit
control
antibodi
detect
sampl
either
anim
addit
experi
repetit
inject
subcutan
challeng
da
rat
produc
antibodi
week
schaal
et
al
manuscript
prepar
macrocycl
conform
confer
remark
resist
enzymat
degrad
properti
confound
initi
attempt
determin
peptid
coval
structur
complet
stabl
heat
min
extend
storag
ph
tran
selst
unpublish
data
evalu
stabil
human
serum
edtaanticoagul
plasma
mgml
human
serum
albumin
incub
mixtur
h
time
zero
concentr
determin
quantit
rphplc
mixtur
ident
within
limit
method
precis
h
incub
level
rel
time
zero
serum
plasma
albumin
demonstr
peptid
stabl
biolog
fluid
consist
data
also
highli
stabl
whole
blood
human
rat
mice
least
h
data
shown
evalu
effect
vivo
use
two
mous
model
bacteri
periton
singl
subcutan
dose
mgkg
significantli
improv
surviv
mice
infect
intraperiton
live
e
coli
fig
anim
peptid
salin
control
surviv
beyond
day
clinic
normal
death
occur
cours
trial
day
fig
plasma
cytokinechemokin
level
treat
untreat
bacterem
mice
analyz
cohort
mice
treatment
group
euthan
hour
post
challengetreat
untreat
bacterem
anim
mark
elev
tnf
vegf
fig
treatment
result
reduct
cytokin
decreas
vegf
statist
signific
cytokinechemokin
level
uninfect
treat
anim
unalt
compar
salin
treat
control
also
evalu
effect
balbc
mice
render
septic
cecal
ligat
punctur
salin
treat
anim
die
within
day
clp
surgeri
singl
iv
dose
mgml
administ
h
clp
surgeri
result
long
term
surviv
mice
fig
surprisingli
mice
treat
h
post
clp
also
recov
clinic
normal
end
trial
result
studi
present
reveal
hdefensin
possess
potent
antiinflammatori
properti
vitro
vivo
previou
studi
suppress
pulmonari
bronchiol
level
proinflammatori
cytokin
induc
sarscov
ssrna
viru
treatment
ssrnastimul
pbl
suppress
level
inflammatori
cytokin
chemokin
fig
antiinflammatori
profil
similar
obtain
sarscov
pneumon
model
also
suppress
cytokinechemokin
releas
pbl
stimul
tlr
agonist
includ
tlr
peptid
suppress
tnf
releas
stimul
gramposit
aureu
gramneg
e
coli
bacteria
base
find
specul
effect
due
modul
earli
interact
leukocyt
inflammatori
stimuli
ineffect
neutral
lp
indic
peptid
bind
agonist
unlik
import
antiinflammatori
mechan
differenti
hdefensin
antimicrobi
peptid
bind
neutral
lp
preincub
experi
describ
fig
reveal
rapidli
block
e
colistimul
tnf
releas
human
blood
tempor
analys
mix
experi
implic
peptideleukocyt
interact
critic
determin
tnf
blockad
time
scale
inhibitori
effect
minut
suggest
hdefensin
may
disrupt
mobil
tnf
surfac
stimul
cell
sinc
tnf
play
central
role
trigger
sustain
inflammatori
cascad
hdefensin
blockad
tnf
may
suppress
subsequ
inflammatori
respons
therebi
reduc
level
inflammatori
cytokineschemokin
vitro
fig
vivo
fig
altern
hdefensin
may
interrupt
tnf
autocrin
circuit
amplifi
effect
acut
phase
cytokin
suppress
rtdmediat
tnf
releas
common
featur
antigenstimul
leukocyt
respons
vitro
yet
identifi
downstream
mechan
result
regul
secondari
proinflammatori
cytokineschemokin
context
effect
inflammatori
mediat
blockad
highli
complex
context
depend
like
involv
crosstalk
signal
factor
differenti
induc
distinct
tlr
agonist
stimuli
produc
protect
andor
patholog
respons
thu
surpris
immunomodulatori
effect
vari
function
inflammatori
stimuli
correl
vitro
effect
analyz
use
whole
blood
pbl
monocytemacrophag
effect
observ
vivo
eg
sepsi
model
must
interpret
caution
regard
rel
modest
effect
systemicallyadminist
plasma
cytokin
bacterem
mice
contrast
dramat
regul
cytokin
occur
leukocyt
treat
hdefensin
vitro
appar
discrep
observ
mani
vitroin
vivo
model
comparison
evid
pathway
induc
hdefensin
vivo
eg
fig
requir
investig
delin
mechan
confer
efficaci
model
context
treatment
pbl
produc
reproduc
elev
vegfa
howev
peptid
effect
vivo
fact
significantli
reduc
vegfa
level
bacterem
mice
fig
lung
protect
patholog
role
ascrib
vegf
physiolog
regul
appear
play
critic
role
outcom
pulmonari
acut
lung
injuri
acut
respiratori
distress
syndrom
induct
leukocyt
vegfa
may
repres
new
mechan
wherebi
circul
cell
stimul
releas
vascular
growth
factor
local
express
hdefensin
interest
note
human
neutrophil
adefensin
inhibit
vegfdepend
neovascular
potenti
highlight
anoth
differ
aand
hdefensin
studi
underway
analyz
mechan
underli
induct
vegfa
hdefensin
stimul
leukocyt
despit
fact
known
hdefensin
invari
acid
core
structur
fig
five
hdefensin
isoform
vari
significantli
blockad
e
coli
lpsstimul
inflammatori
respons
hierarchi
antitnf
potenc
two
cellular
assay
correl
peptid
charg
antitnf
efficaci
fact
effect
least
effect
peptid
net
charg
human
adefensin
share
none
antiinflammatori
properti
observ
hdefensin
surpris
given
lack
structur
similar
aand
hdefensin
fact
adefensin
possess
proinflammatori
properti
includ
regul
tnf
express
monocyt
stimul
tnf
express
myeloid
dendrit
cell
induct
releas
lung
epitheli
cell
macrocycl
structur
hdefensin
confer
remark
stabil
unmodifi
incub
day
freshli
prepar
plasma
serum
also
welltoler
administ
intraven
subcutan
mice
rat
chimpanze
follow
repeat
inject
neither
two
chimpanze
produc
antibodi
biocompat
enabl
evalu
therapeut
potenti
anim
model
system
inflamm
discoveri
antimicrobi
peptid
proven
role
host
defens
prompt
studi
evalu
divers
peptid
deriv
human
cell
ungul
indolicidin
sheep
myeloid
antimicrobi
peptid
smap
pig
protegrin
preclin
bacteremia
model
protect
lethal
bacteremia
indolicidin
observ
follow
singl
system
administr
peptid
time
bacteri
challeng
therapeut
effect
figur
increas
surviv
e
coli
periton
modul
cytokinechemokin
balbc
mice
challeng
cfu
e
coli
treat
simultan
sc
inject
salin
n
n
mgkg
n
endpoint
surviv
data
plot
subject
x
analysi
pvalu
day
later
b
plasma
cytokineschemokin
quantifi
blood
obtain
anim
euthan
n
time
point
h
ip
challeng
treatment
salin
n
mgkg
sham
control
inject
alon
cytokineschemokin
quantifi
describ
method
result
subject
student
ttest
p
case
attribut
antiendotox
activ
respect
peptid
contrast
clp
sepsi
multipl
dose
porcin
protegrin
littl
endotoxinneutr
effect
treatment
regimen
produc
therapeut
effect
compar
vehicl
control
data
present
suggest
alter
cours
diseas
two
model
bacterem
sepsi
manner
differ
exampl
singl
dose
administr
either
e
coli
periton
clp
sepsi
produc
therapeut
respons
former
model
simultan
modest
reduct
inflammatori
cytokin
observ
treat
anim
surprisingli
singl
dose
rescu
mice
render
septic
clp
surgeri
even
treatment
delay
periton
induc
efficaci
hdefensin
model
appear
independ
direct
antiendotox
effect
sinc
peptid
ineffect
block
effect
endotoxin
limulu
amoebocyt
assay
current
studi
underway
character
mechanist
base
immunomodulatori
activ
hdefensin
vitro
vivo
lack
immunogen
toxic
across
speci
rais
possibl
hdefensin
may
util
human
therapeut
